JAZZ PHARMACEUTICALS WKN: A1JS1K ISIN: IE00B4Q5ZN47 Forum: Aktien Thema: Hauptdiskussion

Jazz Pharmaceuticals resumed with a Buy at Goldman Sachs TheFly Sep 24, 2026, 08:51 AM Goldman Sachs resumed coverage of Jazz Pharmaceuticals (JAZZ) with a Buy rating and $337 price target Goldman resumed coverage of the biotechnology sector, saying the group has continued to outperform despite a backdrop of elevated macro volatility and rising interest rates. The rally has been supported by robust acquisition activity, positive clinical catalysts, and a more constructive regulatory outlook, the analyst tells investors in a research note. Goldman favors companies with “de-risked commercial execution and underappreciated pipeline optionality.”

Gerade eben: Goldman Sachs auf 'buy' mit $ 337

Das durchschnittliche Kursziel liegt zwischen $ 225 und $ 337!?

Arrowhead Pharmaceuticals (ARWR) Receives a Rating Update from a Top Analyst TipRanks Auto-Generated Intelligence Newsdesk Sep 21, 2026, 05:55 PM H.C. Wainwright analyst Patrick Trucchio maintained a Buy rating on Arrowhead Pharmaceuticals today and set a price target of $120.00. Trucchio covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Alnylam Pharma, and Voyager Therapeutics. According to TipRanks, Trucchio has an average return of 36.3% and a 55.24% success rate on recommended stocks. Arrowhead Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $113.50.

Jazz Pharmaceuticals Refinances Term Loan, Extends Maturities TipRanks Auto-Generated Newsdesk Sep 23, 2026, 08:52 PM On September 23, 2026, Jazz Financing Lux S.à r.l., a wholly owned subsidiary of Jazz Pharmaceuticals, entered into a fourth amendment to its existing credit agreement to extend the maturity and reprice its U.S. dollar term loan B-2 facility originally incurred on July 19, 2024. Certain existing lenders converted their Tranche B-2 Dollar Term Loans into a new Tranche B-3 Dollar Term Loans, while Jazz Lux raised an additional $273.3 million in Tranche B-3 loans to repay remaining Tranche B-2 borrowings, maintaining substantially the same key terms as prior tranches and effectively refinancing its debt on updated pricing and tenor terms. The creation of the Tranche B-3 Dollar Term Loans, with terms aligned to earlier facilities dating back to May 5, 2021, underscores Jazz Pharmaceuticals’ continued use of the leveraged loan market to manage its balance sheet. By extending maturities and adjusting pricing without materially changing covenants, security or default provisions, the company preserves financial flexibility for operations and investments while providing lenders with a restructured but familiar credit profile.

Jazz Pharmaceuticals price target raised to $337 from $315 at UBS TheFly Sep 11, 2026, 12:00 PM UBS raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $337 from $315 and keeps a Buy rating on the shares. Jazz’s post-GEA approval of Ziihera supports near- to medium-term outperformance, while expansion into breast, colorectal, and lung cancers could unlock substantial incremental long-term value and help broaden ownership as management builds toward its newly raised $3B-$5B peak-sales outlook, the analyst tells investors in a research note.

So etwas ähnliches hat meine KI auch gemeldet. Da der ganze Sektor wegen KI (durch verkürzte Forschung bzw Versuchsreihen) und Alterung der Bevölkerung boomt, ist es nur eine Frage der Zeit, bis auch Jazz davon profitiert..

Jazz Pharmaceuticals (JAZZ) Needham analyst Ami Fadia reiterated a Buy rating on Jazz Pharmaceuticals today and set a price target of $310.00. The company’s shares closed last Friday at $244.54. According to TipRanks.com, Fadia is a top 100 analyst with an average return of 35.1% and a 59.6% success rate. Fadia covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Praxis Precision Medicines, and Neumora Therapeutics, Inc. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Jazz Pharmaceuticals with a $291.53 average price target, which is a 16.9% upside from current levels. https://archive.is/GWcCT#selection-3111.0-3141.302

https://www.tipranks.com/news/company-announcements/jazz-pharmaceuticals-announces-positive-phase-3-trial-results

😎

Aber hier lag der Schlingel verkehrt hab direkt nach seiner Empfehlung investiert und das war genau der Höhepunkt seitdem locker über 10 % verloren. Der Schlingel ist auch nicht besser als andere Trefferquote 50 %

Hab mal ne Posi hinterlegt,der Gauner Phantom by HKCM hat die Aktie empfohlen und bei Palantir lag der Schlingel richtig... schau mer mal.

Jmd hier drin, überlege reinzugehen

Was würde eine mögliche DEA I auf III Entscheidung bewirken??

Nix los hier? Die Aktie wird aktuell von den Analysten gelobt